Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324928 | 1.00 | HPGD (0.40) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL29874341 | 0.93 | PRMT5 (0.41) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL20362162 | 0.82 | MGMT (0.30) | — | |
| SCHEMBL15362664 | 0.82 | HPGD (0.46) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL21458709 | 0.82 | HPGD (0.46) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL21458682 | 0.82 | HPGD (0.46) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL30869902 | 0.82 | HPGD (0.46) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL16302472 | 0.82 | HPGD (0.46) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL21458526 | 0.81 | HPGD (0.45) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL21458885 | 0.81 | HPGD (0.45) | HPGDRECQLEPHX1GPR119PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | SLC10A1, SLC10A2, SLC9A2 | HPGD 384/4885RECQL 2300/4885EPHX1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.